FAIRFIELD, N.J., Aug. 9 /PRNewswire-FirstCall/ -- Bradley
Pharmaceuticals, Inc. (NYSE: BDY), today announced Daniel Glassman,
Chairman and Chief Executive Officer, will host a conference call to
discuss the Company's Second Quarter 2006 Earnings on Thursday, August 17,
2006 at 8:30 AM ET. To participate in the conference call, please dial
1-888-573-3046 approximately 10 minutes prior to the start of the call and
enter ID# 4097394.
Playback of the conference call will be available after 1:00 PM ET by
calling 1-800-642-1687 and entering reservation ID# 4097394. The call also
will be available on our web page for 30 days.
Bradley Pharmaceuticals, Inc. (NYSE: BDY) was founded in 1985 as a
specialty pharmaceutical company and markets to niche physician specialties
in the U.S. and 38 international markets. Bradley's success is based on the
strategy of Acquire, Enhance and Grow. Bradley Acquires non-strategic
brands, Enhances these brands with line extensions and improved
formulations and Grows the products through promotion, advertising and
selling activities to optimize life cycle management. Bradley
Pharmaceuticals is comprised of Doak Dermatologics, specializing in topical
therapies for dermatology and podiatry; Kenwood Therapeutics, providing
gastroenterology, respiratory and other internal medicine brands; and A.
Aarons, which markets authorized generic versions of Doak and Kenwood
therapies.
Important announcement:
Daniel Glassman will present at the RBC's Healthcare Conference, to be
held in New York City, December 12-14, 2006.
Daniel Glassman will present at the Raymond James & Associates 28th
Annual Institutional Investors Conference, to be held at the Hyatt Regency
Grand Cypress in Orlando, FL., March 4-7, 2007.
Please visit Bradley Pharmaceuticals web site at:
http://www.bradpharm.com
Bradley Pharmaceuticals common stock is listed on the NYSE under the
symbol BDY.
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. Forward-
looking statements include statements that address activities, events or
developments that Bradley expects, believes or anticipates will or may
occur in the future, such as sales and earnings estimates, other
predictions of financial performance, timing of payments on indebtedness,
launches by Bradley of new products and market acceptance of Bradley's
products. Forward-looking statements are based on Bradley's experience and
perception of current conditions, trends, expected future developments and
other factors it believes are appropriate under the circumstances and are
subject to numerous risks and uncertainties, many of which are beyond
Bradley's control. These risks and uncertainties include Bradley's ability
to estimate sales; ability to comply with the restrictive covenants under
its credit facility; ability to refinance its credit facility, if
necessary; ability to access the capital markets on attractive terms or at
all; ability to favorably resolve the pending SEC informal inquiry and file
required financial statements with the SEC in a timely manner; remediate
its material weaknesses in its internal controls; maintain sales of its
products; successfully acquire, develop, integrate, or sell new products,
including POLYPHENON(R) E Ointment when and if approved by the FDA; or
effectively react to other risks and uncertainties described from time to
time in Bradley's SEC filings, such as fluctuation of quarterly financial
results, estimation of product returns, chargebacks, rebates and
allowances, concentration of customers, reliance on third party
manufacturers and suppliers, litigation or other proceedings (including the
pending class action, shareholder derivative lawsuits and controversies or
proceedings arising out of a potential shareholder-initiated proxy contest
at our annual meeting), government regulation and stock price volatility.
Further, Bradley cannot accurately predict the impact on its business of
the approval, introduction, or expansion by competitors of generic or
therapeutically equivalent or comparable versions of Bradley's products or
of any other competing products. In addition, actual results may differ
materially from those projected. Bradley undertakes no obligation to
publicly update any forward-looking statement, whether as a result of new
information, future events or otherwise.
SOURCE Bradley Pharmaceuticals, Inc.
 back to top
Related links:
http://www.bradpharm.com
CONTACT:
Anthony Griffo, Investor Relations, of
Bradley Pharmaceuticals, Inc., +1-973-882-1505, ext. 313
|
